Healius Limited

Mitsubishi UFJ Financial Group Acquires 5.22% Stake in Healius Limited

Healius Limited has announced significant changes to its Board of Directors, with the resignation of Dr. Michael Stanford and Mr. Neil Vinson, and the appointment of Mr. Steven Rubic and Mr. Chris Hall as new Non-Executive Directors. These changes aim to align with Healius’ strategic goals, particularly the T27 strategy, which is vital for future growth. The current analyst rating for Healius Limited (AU:HLS) is a Hold with a price target of A$0.87, and the company operates in the healthcare sector with a market cap of A$541M.

Tip Ranks

Healius Limited Announces Strategic Board Changes

Healius Limited's Director John Mattick has increased his shareholding by acquiring 200,000 ordinary shares, signaling confidence in the company's future performance. The current analyst rating for Healius (AU:HLS) is a Hold with a price target of A$0.87. Healius operates in the healthcare sector, providing medical and diagnostic services across Australia, with a market cap of A$624.5M.

Healius Director Increases Shareholding, Signaling Confidence

Mitsubishi UFJ Financial Group has acquired a 5.22% stake in Healius Limited, indicating a significant investment that may influence the company's market dynamics and shareholder structure. The latest analyst rating for Healius Limited (AU:HLS) is a Hold, with a price target of A$1.65. Healius Limited currently has a market cap of A$551.9M and an average trading volume of 5,317,242 shares.

Mitsubishi UFJ Financial Group Acquires Substantial Stake in Healius Limited

Healius Limited announced that Perpetual Limited and its related bodies corporate have ceased to be substantial holders in the company as of May 27, 2025. This change may affect Healius's market dynamics and stakeholder relationships, as substantial holders typically influence company decisions. The latest analyst rating for Healius Limited (AU:HLS) is a Hold with a price target of A$1.65. Healius operates in the healthcare sector, providing medical and diagnostic services across Australia, with a current market cap of A$642.6M.

Perpetual Limited

Perpetual Limited Ceases to be Substantial Holder in Healius Limited

Healius Limited (AU:HLS) hosted its Investor Day on March 27, 2025, via webcast and in-person at UBS in Sydney. The event experienced minor issues with webcast registration confirmations, emphasizing the company's commitment to transparency. Healius has been a prominent healthcare provider in Australia for over 30 years, specializing in pathology and imaging services. The company's current market cap is €568.1M, with a year-to-date price performance of -12.80% and a strong buy technical sentiment signal.

Healius Limited Hosts Investor Day with Webcast and In-Person Attendance

Perpetual Limited has reduced its stake in Healius Limited from 11.15% to 9.785%, affecting its voting power and potentially influencing market perceptions of Healius's strategic direction. Healius Limited, operating in the healthcare sector, provides medical and diagnostic services in Australia, focusing on accessible healthcare solutions. The company's current market cap is €573.8M, with a year-to-date price performance of -5.52% and a strong buy consensus rating.

Perpetual Limited Reduces Stake in Healius Limited

Healius Limited reported a 10% revenue increase for H1 FY25, totaling $933.9 million, with positive growth in underlying EBITDA and EBIT. The pathology division grew by 7%, while Lumus Imaging saw a 13.3% revenue boost. Healius plans to return proceeds from the sale of Lumus Imaging to shareholders via a special dividend. The company is opposing government cuts to certain pathology tests, which may affect future revenues. Current market cap stands at €642.2M with a strong buy consensus rating.

Healius Limited Reports Strong Revenue Growth Amid Strategic Changes

Healius Limited (AU:HLS) has updated its director's shareholding structure, as required by listing rule 3.19A.2. Director Sally Evans transferred 49,528 ordinary shares through an off-market in-specie transfer, with no change to her beneficial ownership. This adjustment reflects internal changes in shareholding but does not affect overall ownership or control of the company. Healius Limited's current market cap is €615.2M, with a strong buy consensus rating and a year-to-date price performance of 1.23%.

ING Groep

Healius Limited Updates Director’s Shareholding Structure

Healius Limited (AU:HLS) will announce its HY 2025 results on February 20, 2025, followed by an analyst and investor briefing. This event is crucial for understanding the company's operational performance in the healthcare sector, which may influence stakeholder decisions and market positioning. Healius Limited provides a variety of medical services and laboratory testing solutions across Australia, focusing on accessible healthcare for both public and private sectors. Current market cap is €633.6M with a strong buy consensus rating.